OneMedNet Regains Compliance with NASDAQ Minimum Bid Price Requirements
OneMedNet (ONMD) has successfully regained compliance with Nasdaq's minimum bid price requirement, maintaining a closing bid price of $1.00 or higher for 10 consecutive business days. The company has implemented several strategic initiatives in the second half of 2024, including key executive appointments such as Bob Golden as CFO, Margaret Nash as Director of Business Development, and Michael Wong as VP of Marketing.
The company has enhanced its operations by improving its Data De-Identification service with Generative AI, deploying the OMNi 2.0 indexer, and signing an agreement with Bayer's AI Innovation Platform. Financial improvements include raising approximately $6.4M through private placements with Off the Chain Capital and Discovery Capital Management affiliate, alongside implementing a Bitcoin treasury management strategy.
OneMedNet (ONMD) ha ripristinato con successo la conformità ai requisiti di prezzo minimo per le offerte di Nasdaq, mantenendo un prezzo di offerta di chiusura di $1,00 o superiore per 10 giorni lavorativi consecutivi. L'azienda ha attuato diverse iniziative strategiche nella seconda metà del 2024, comprese nomine chiave come Bob Golden come CFO, Margaret Nash come Direttore dello Sviluppo Commerciale e Michael Wong come VP di Marketing.
L'azienda ha migliorato le proprie operazioni potenziando il servizio di De-identificazione dei Dati con l'AI Generativa, implementando l'indicizzatore OMNi 2.0 e firmando un accordo con la piattaforma AI Innovation di Bayer. I miglioramenti finanziari includono la raccolta di circa $6,4 milioni tramite collocamenti privati con Off the Chain Capital e l'affiliato di Discovery Capital Management, insieme all'implementazione di una strategia di gestione del tesoreria in Bitcoin.
OneMedNet (ONMD) ha recuperado exitosamente el cumplimiento del requisito de precio mínimo por oferta de Nasdaq, manteniendo un precio de oferta de cierre de $1.00 o más durante 10 días hábiles consecutivos. La empresa ha implementado varias iniciativas estratégicas en la segunda mitad de 2024, incluidas nombramientos clave como Bob Golden como CFO, Margaret Nash como Directora de Desarrollo Comercial y Michael Wong como VP de Marketing.
La empresa ha mejorado sus operaciones al potenciar su servicio de Desidentificación de Datos con IA Generativa, desplegando el indexador OMNi 2.0 y firmando un acuerdo con la Plataforma de Innovación en IA de Bayer. Las mejoras financieras incluyen la recaudación de aproximadamente $6.4 millones a través de colocaciones privadas con Off the Chain Capital y el afiliado de Discovery Capital Management, junto con la implementación de una estrategia de gestión de tesorería en Bitcoin.
OneMedNet (ONMD)는 나스닥의 최소 경매 가격 요구 사항을 성공적으로 회복하여 10일 연속으로 $1.00 이상의 종가 모집가를 유지했습니다. 이 회사는 2024년 하반기에 Bob Golden을 CFO로, Margaret Nash를 비즈니스 개발 이사로, Michael Wong을 마케팅 VP로 임명하는 등 여러 전략적 이니셔티브를 구현했습니다.
회사는 생성적 AI를 활용하여 데이터 비식별화 서비스를 개선하고 OMNi 2.0 인덱서를 배포하며 Bayer의 AI 혁신 플랫폼과 계약을 체결함으로써 운영을 강화했습니다. 재정 개선은 Off the Chain Capital 및 Discovery Capital Management의 제휴를 통해 약 $6.4M을 모금하고 비트코인 자산 관리 전략을 시행한 것을 포함합니다.
OneMedNet (ONMD) a réussi à retrouver la conformité avec l'exigence de prix d'offre minimum de Nasdaq, en maintenant un prix de clôture d'offre de 1,00 $ ou plus pendant 10 jours ouvrables consécutifs. L'entreprise a mis en œuvre plusieurs initiatives stratégiques dans la seconde moitié de 2024, y compris des nominations clés comme Bob Golden au poste de CFO, Margaret Nash en tant que directrice du développement commercial et Michael Wong au poste de VP marketing.
L'entreprise a renforcé ses opérations en améliorant son service de désidentification des données avec l'IA générative, en déployant l'indexeur OMNi 2.0 et en signant un accord avec la plateforme d'innovation par IA de Bayer. Les améliorations financières incluent la levée d'environ 6,4 millions de dollars grâce à des placements privés avec Off the Chain Capital et l'affilié de Discovery Capital Management, ainsi que l'implémentation d'une stratégie de gestion de trésorerie en Bitcoin.
OneMedNet (ONMD) hat erfolgreich die Anforderungen des Nasdaq an den Mindestgebotspreis wiederhergestellt und einen Schlussgebotspreis von $1,00 oder höher für 10 aufeinanderfolgende Geschäftstage aufrechterhalten. Das Unternehmen hat in der zweiten Hälfte des Jahres 2024 mehrere strategische Initiativen umgesetzt, darunter wichtige Ernennungen wie Bob Golden als CFO, Margaret Nash als Direktorin für Geschäftsentwicklung und Michael Wong als VP für Marketing.
Das Unternehmen hat seine Abläufe verbessert, indem es seinen Dienst zur Daten-De-Identifizierung mit generativer KI optimiert, den OMNi 2.0-Indexer bereitgestellt und einen Vertrag mit der AI Innovation Platform von Bayer unterzeichnet hat. Zu den finanziellen Verbesserungen gehört die Beschaffung von rund $6,4 Millionen durch Privatplatzierungen mit Off the Chain Capital und dem Tochterunternehmen von Discovery Capital Management sowie die Implementierung einer Bitcoin-Treasury-Management-Strategie.
- Regained Nasdaq compliance, eliminating delisting risk
- Secured $6.4M in private placement funding
- Signed partnership agreement with Bayer's AI Innovation Platform
- Enhanced data services with Generative AI implementation
- None.
Insights
The compliance achievement with NASDAQ's minimum bid price requirement represents a critical milestone for OneMedNet, particularly given its modest market cap of
The
The appointment of key executives in finance, business development and marketing, coupled with the board refresh, indicates a pivot toward commercial expansion in the life sciences sector. The Bayer AI Innovation Platform partnership could be particularly valuable for scaling the company's imaging Real World Data offerings.
For retail investors, while regaining NASDAQ compliance removes immediate delisting concerns, the company's small market capitalization and emerging business model in the competitive healthcare data analytics space warrant careful consideration. The integration of GenAI into their data services shows technological progression but will require significant execution to translate into sustainable revenue growth.
The deployment of OneMedNet's 2.0 generation indexer OMNi and integration of Generative AI into their data de-identification processes represents a significant technological upgrade. In the medical imaging data space, efficient indexing and searching capabilities are important differentiators, as they directly impact the speed and accuracy of data retrieval for research and analysis.
The partnership with Bayer's AI Innovation Platform (AIIP) is particularly noteworthy, as it provides validation of OneMedNet's technological capabilities from a major pharmaceutical player. The combination of imaging Real World Data (iRWD™) with electronic health records and laboratory results creates a comprehensive data ecosystem that could be valuable for drug development and clinical research.
However, the implementation of blockchain technology for treasury management, while innovative, introduces technological and regulatory complexity that may divert resources from core product development. The focus should remain on enhancing their data curation and analytics capabilities to capitalize on the growing demand for healthcare real-world data.
MINNEAPOLIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (“iRWD™”), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that the Company regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”) after the closing bid price of the Company’s common stock was
Aaron Green, Chief Executive Officer, stated, “We are pleased to have now achieved compliance with both the Nasdaq minimum bid price rule and Nasdaq’s periodic financial reporting rule.”
As the Company previously announced, during the second half of 2024, we developed and started to execute on our strategic plan by:
- Appointing Bob Golden as Chief Financial Officer to oversee enhancements in the Company’s financial reporting processes.
- Hiring a Director of Business Development, Margaret Nash, and Vice President of Marketing, Michael Wong, to continue to build our commercial presence with Life Science organizations, additionally recently signing an agreement with Bayer’s AI Innovation Platform (AIIP) announced in early December.
- Enhancing our Data De-Identification and curation service leveraging Generative AI and deploying OneMedNet’s 2.0 generation indexer OMNi, to improve the speed and accuracy of data searching and indexing.
- Refreshing the composition of the Company’s Board of Directors with three new directors who have relevant industry, financial and public company expertise.
- Improving liquidity by raising approximately
$6.4M in private placements with Off the Chain Capital and an affiliate of Discovery Capital Management. - Enhancing treasury management with a Bitcoin on the balance sheet strategy.
OneMedNet is now in a position to take advantage of the growing Real World Data market with a meaningful market share.
About OneMedNet Corporation
OneMedNet provides innovative solutions that unlock the significant value contained within the Real-World Data (“RWD”) repositories of over 1,400 healthcare system and provider sites that currently comprise its iRWD™ network. OneMedNet’s proprietary iRWD™ platform provides secure, comprehensive management of diverse clinical data types, including electronic health records, ECGs, EEGs, prescriptions, physician notes, laboratory results, and uniquely, medical imaging. Employing its robust iRWD™ platform, the Company securely de-identifies, searches, and curates the clinical data, bringing a wealth of internal and third-party research opportunities to its drug, medical device and imaging/diagnostic AI development customers.
OneMedNet’s platform is designed to address diverse clinical requirements across various domains, such as rare diseases, central nervous system disorders, oncology, cardiology and women’s health. The Company is committed to delivering precise and robust research support services that span the entire continuum of care. This commitment is a cornerstone of OneMedNet’s strategy to enhance patient outcomes and help pave the next wave of healthcare innovation. For more information, please visit www.onemednet.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timeline for the Company to regain compliance with the listing rules of The Nasdaq Stock Market LLC relating to maintaining a minimum value of listed securities; risks inherent with investing in Bitcoin, including Bitcoin’s volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: michael.wong@onemednet.com
SOURCE: ONEMEDNET CORPORATION
FAQ
How did OneMedNet (ONMD) regain Nasdaq compliance?
How much funding did ONMD raise in their recent private placements?
What strategic appointments did ONMD make in 2024?
What technological improvements has ONMD implemented recently?
What major partnership did ONMD secure in December 2024?
